CDC
Bundibugyo Ebola outbreak: what U.S. clinicians need to know now
Clinical takeaway: For any febrile traveler recently returned from the Democratic Republic of Congo, Uganda, or South Sudan, take a detailed travel and exposure history, test promptly for malaria, and trigger immediate infection-control and public-health consultation if Ebola is a concern.
During a CDC Clinician Outreach and Communication Activity (COCA) Call broadcast on May 28, 2026, experts outlined key clinical considerations related to a rapidly evolving outbreak of Ebola Bundibugyo virus (BDBV) in the Democratic Republic of Congo (DRC) and Uganda. While more than 1,000 suspected cases have been reported in the region, “the risk to the U.S. general public is low,” and no U.S. cases have been identified to date.
The outbreak was initially detected after a cluster of severe illnesses—including among healthcare workers—tested negative for the more common Zaire strain, delaying identification. Subsequent testing confirmed Bundibugyo virus, a less common Ebola species with limited historical data. “This is a rapidly evolving situation, and we are learning more every day,” presenters noted.
Bundibugyo virus is one of four Ebola viruses that cause human disease and is clinically indistinguishable from other forms of Ebola. Transmission occurs via direct contact with infected body fluids or contaminated materials, not through airborne spread. Symptoms remain nonspecific—fever, fatigue, headache, vomiting, and diarrhea—with hemorrhagic findings occurring later and inconsistently. “There is no sign or symptom that is pathognomonic for Ebola disease,” clinicians were reminded, and fever may be absent in a significant subset of cases.
Given the nonspecific presentation, travel history is critical. Clinicians should consider Ebola in any ill traveler returning from affected areas—but not at the expense of more likely diagnoses. “Malaria is the most common cause of undifferentiated fever after travel to sub-Saharan Africa,” experts emphasized, adding that malaria testing should never be delayed and co-infection is possible.
RT-PCR remains the diagnostic standard, but timing matters: a negative result within 72 hours of symptom onset does not rule out infection. There are currently no FDA-approved therapies or vaccines for Bundibugyo virus, though early supportive care—especially aggressive hydration and electrolyte management—can improve outcomes.
Strict infection prevention and control (IPC) practices were reinforced throughout the call. The CDC’s “identify, isolate, inform” framework remains essential, with rapid triage, prompt patient isolation, and early public health notification critical to limiting exposure. “Early identification and isolation are critical to minimizing transmission,” presenters stressed, noting that patients become increasingly contagious as illness progresses.
Enhanced travel screening and routing through designated U.S. airports are in place to mitigate importation risk. Still, frontline clinicians remain a key defense. Early recognition, appropriate precautions, and coordination with public health partners are central to preventing spread and ensuring safe patient care.
Source: May 28, 2026. CDC Clinician Outreach and Communication Activity (COCA) Call, “What Clinicians Should Know about Ebola Bundibugyo Virus”